Human alpha-galactosidase variants
AssigneeCodexis, Inc.
InventorsNicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
Life of this patent
Estimating the term…
Abstract
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH <4.5) and basic (pH >7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
Claims35
A recombinant alpha galactosidase A and/or biologically active recombinant alpha galactosidase A fragment comprising an amino acid sequence comprising at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to SEQ ID NO:5.
A recombinant alpha galactosidase A comprising the polypeptide sequence of SEQ ID NO:15, 13, 10, 18, 40, 42, 44, or 46.
Dependencies are inferred from the claim text.